To succeed in developing targeted medicines, companies need a biomarker strategy and the expertise to make smart decisions about clinical trial design, assays, technology platforms and collaborative partners, write Barry S. Sall and Angela X. Qu.
Barry S. Sall, Angela X. Qu, MD, PhD
Advertisement
Barry S. Sall is Principal Consultant, Parexel Consulting. Angela X. Qu, MD, PhD, is Senior Director â Biomarkers & Genomic Medicine, Parexel.
Articles by Barry S. Sall, Angela X. Qu, MD, PhD
Advertisement
Latest Updated Articles
Navigating the Increasing Complexity of Drug-Biomarker Co-DevelopmentPublished: September 10th 2018 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Thermo Fisher Enters $8.8 Billion Definitive Agreement to Acquire Clario Holdings
2
What Impact will FDA's ANDA Prioritization Pilot have on the Global Supply Chain?
3
Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns
4
FDA Approves Single-Injection, Once-Monthly Maintenance Regimen for Lilly’s Omvoh in Ulcerative Colitis
5
